Systematic analysis of COVID-19 mRNA vaccines using four orthogonal approaches demonstrates no excessive DNA impurities

All data generated or analysed during this study are included in this published article and its supplementary information file. Unmodified short-read sequences were deposited in NCBI under Project ID PRJNA1303864 and are accessible via https://www.ebi.ac.uk/ena/browser/view/PRJNA1303864, or https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1303864/.

1. Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines – A new era in vaccinology. Nat. Rev. Drug. Discov. 17, 261–279 (2018).

   Google Scholar 

2. Guidance for Industry – Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications, U.S. DHHS, FDA, CBER, February 2010.

3. Paul-Ehrlich-Institut 2023. Information for Healthcare professionals. Testing of COVID-19 mRNA vaccines. https://www.pei.de/SharedDocs/Downloads/EN/newsroom-en/notification/231222-testing-mrna-vaccinas-dna-contamination.pdf?__blob=publicationFile&v=3.

4. European Commission, Directorate-General for Health and Food Safety: ADVANCE PURCHASE AGREEMENT („APA”) for the development, production, priority-purchasing options and supply of a successful COVID-19 vaccine for EU Member States. SANTE/2020/C3/043 -S1I2.838335 (2020).

5. Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug. Discov. 20, 817–838 (2021).

   Google Scholar 

6. Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586 (2021).

   Google Scholar 

7. Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W. & Mastrobattista, E. Addressing the cold reality of mRNA vaccine stability. J. Pharm. Sci. 110, 997–1001 (2021).

   Google Scholar 

8. Kaiser, S., Kaiser, S., Reis, J. & Marschalek, R. Quantification of objective concentrations of DNA impurities in mRNA vaccines. Vaccine 55, 127022 (2025).

   Google Scholar 

9. Leban, M. et al. Determination of linearized pDNA template in mRNA production process using HPLC. Anal. Bioanal. Chem. 416, 2389–2398 (2024).

   Google Scholar 

10. Vieth, S., Waibler, Z. & Schumann, G. G. Opting for the appropriate methodology for quantification of residual DNA impurities in mRNA vaccines. Vaccine 56, 127186 (2025).

    Google Scholar 

11. Kämmerer, U., Schulz, V. & Steger, K. BioNTech RNA-Based COVID-19 Injections Contain Large Amounts Of Residual DNA Including An SV40 Promoter/Enhancer Sequence. https://publichealthpolicyjournal.com/biontech-rna-based-covid-19-injections-contain-large-amounts-of-residual-dna-including-an-sv40-promoter-enhancer-sequence/ (2024).

12. König, B. & Kirchner, J. O. Methodological considerations regarding the quantification of DNA impurities in the COVID-19 mRNA vaccine comirnaty®. Methods Protoc. 7, 41 (2024).

    Google Scholar 

13. Speicher, D. J., Rose, J. & McKernan, K. Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada. Autoimmunity 58, 2551517 (2025).

    Google Scholar 

14. McKernan, K., Helbert, Y., Kane, L. T. & McLaughlin, S. Sequencing of bivalent Moderna and Pfizer mRNA vaccines reveals nanogram to microgram quantities of expression vector dsDNA per dose. Preprint at https://doi.org/10.31219/osf.io/b9t7m (2023).

15. Fleming, R. M., Kotlar, P. & Pekova, S. Quantitative analysis of nucleic acid content in spikevax (Moderna) and BNT162b2 (Pfizer) COVID-19 vaccine lots. HSOA J. Angiol. Vasc. Surg. 10, 124 (2025).

    Google Scholar 

16. Bustin, S. A. et al. MIQE 2.0: revision of the minimum information for publication of quantitative real-time PCR experiments guidelines. Clin. Chem. 71, 634–651 (2025).

    Google Scholar 

17. EUROPEAN PHARMACOPOEIA 01/2020:20635 2.6.35. Quantification and characterisation of host-cell DNA. © Council of Europe, 67075 Strasbourg Cedex, France – 2019.

18. 17 EMA/CHMP/ICH/82072/2006. Committee for Medicinal Products for Human Use, ICH Q2(R2) Guideline on validation of analytical procedures. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal-products-clinical-trials_en.pdf.

19. Minarik, G. et al. Utilization of benchtop next generation sequencing platforms ion torrent PGM and MiSeq in noninvasive prenatal testing for chromosome 21 trisomy and testing of impact of in silico and physical size selection on its analytical performance. PLoS ONE 10, e0144811 (2015).

    Google Scholar 

20. Kucharik, M. et al. Non-invasive prenatal testing (NIPT) by low coverage genomic sequencing: Detection limits of screened chromosomal microdeletions. PLoS ONE 15, e0238245 (2020).

    Google Scholar 

21. Holesova, Z. et al. Understanding genetic variability: exploring large-scale copy number variants through non-invasive prenatal testing in European populations. BMC Genom. 25, 366 (2024).

    Google Scholar 

22. Bao, H., Yang, S., Chen, X. & Zhou, Q. Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics. Nat. Med. https://doi.org/10.1038/s41591-025-03735-2 (2025).

23. Andrews, S. FastQC: a quality control tool for high throughput sequence data. http://www.bioinformatics.babraham.ac.uk/projects/fastqc (2010).

24. Asplund, M. et al. Contaminating viral sequences in high-throughput sequencing viromics: A linkage study of 700 sequencing libraries. Clin. Microbiol. Infect. 25, 1277–1285 (2019).

    Google Scholar 

25. Milne, C. et al. Independent control of COVID-19 vaccines by EU official control authority batch Release: challenges, strengths and successes. npj Vaccines 8, 22 (2023).

    Google Scholar 

26. Therapeutic Goods Administration (TGA), Australian Government, Department of Health and Aged Care. Summary report of residual DNA and endotoxin on COVID-19 mRNA vaccines conducted by TGA Laboratories. https://www.tga.gov.au/resources/publication/tga-laboratory-testing-reports/summary-report-residual-dna-and-endotoxin-covid-19-mrna-vaccines-conducted-tga-laboratories (2024).

27. Therapeutic Goods Administration (TGA), Australian Government, Department of Health and Aged Care. Batch release assessment of COVID-19 vaccines. https://www.tga.gov.au/products/covid-19/covid-19-vaccines/batch-release-assessment-covid-19-vaccines (2025).

28. Wick, R. R., Judd, L. M., Gorrie, C. L. & Holt, K. E. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput. Biol. 13, e1005595 (2017).

    Google Scholar 

29. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).

    Google Scholar 

30. García-Alcalde, F. et al. Qualimap: evaluating next-generation sequencing alignment data. Bioinformatics 28, 2678–2679 (2012).

    Google Scholar 

Download references

Author notes

1. These authors contributed equally: Tomas Szemes, Boris Klempa, Juraj Kopacek, Silvia Pastorekova.

Authors and Affiliations

1. Biomedical Research Center, Slovak Academy of Sciences, Institute of Virology, Bratislava, Slovakia

   Adam Achs, Lukas Predajna, Maria Bartosova, Martina Melichercikova, Boris Klempa, Juraj Kopacek & Silvia Pastorekova

2. Comenius University Science Park, Bratislava, Slovakia

   Tatiana Sedlackova, Jaroslav Budis, Diana Rusnakova & Tomas Szemes

3. Biomedical Research Center, Slovak Academy of Sciences, Biotechnological and Analytical Laboratories, Sarisske Michalany, Slovakia

   Vladimir Zelnik, Marta Miklosova, Veronika Gencurova & Barbora Cernakova

Contributions

S.P., J.K., B.K., and T.Sz. designed the study, A.A., T.Se., L.P., M.B., V.Z., D.R., M.Me., M.Mi., V.G., and B.C. performed the experiments and/or data analysis, J.B. accomplished bioinformatic analysis of sequencing data, S.P. prepared the original manuscript, J.K., B.K., T.Sz., A.A., T. Se., L.P., and J.B. contributed to the writing, reviewing and editing the manuscript. S.P. and J.K. were involved in funding acquisition and project management. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Silvia Pastorekova.

Competing interests

The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions